SCF Translational Development Blueprint

Phase Code: SCF-CF-AEROVIA201-EBP-P8-0001

Program: AEROVIA-CF1A

Development Status: Translational Candidate Blueprint

Therapeutic Classification: Inhaled Pulmonary Neutrophil Elastase Regulatory Modulator

I. PHASE 8 OBJECTIVE

Translate the complete ethnobioprospecting, pathway engineering, formulation, and safety framework into a regulatory-ready translational development blueprint suitable for:

• Hit-to-lead campaigns
• Medicinal chemistry optimization
• Candidate nomination
• IND-enabling development
• First-in-human planning

This phase integrates outputs from Phases 1–7 into a unified preclinical development strategy.

II. FINAL SCF THERAPEUTIC POSITIONING

Clinical Position

AEROVIA-201 is designed as:

Disease-Modifying Adjunctive Therapy

Used alongside:

• CFTR modulators
• Inhaled antibiotics
• Standard cystic fibrosis care

Intended Clinical Problem

Persistent lung destruction despite correction of CFTR dysfunction.

Primary residual drivers:

1. Neutrophilic inflammation
2. Elastase-mediated tissue injury
3. ECM degradation
4. Progressive bronchiectasis
5. Fibrotic remodeling

III. FINAL TRANSLATIONAL HYPOTHESIS

Central Hypothesis

Localized pulmonary modulation of excessive neutrophil elastase activity will:

• Preserve lung architecture
• Reduce protease-mediated injury
• Interrupt inflammatory amplification loops
• Slow structural disease progression

while maintaining sufficient antimicrobial host defense.

IV. FINAL TARGET PRODUCT PROFILE (TPP)

V. FINAL SCF API ARCHITECTURE

Lead API

AEROVIA-201

Primary Function:

Localized modulation of neutrophil elastase.

Supporting Functional Architecture

IRD-201H

Iridoid-inspired cytokine harmonizer.

Function:

• IL-8 modulation
• TNF modulation
• NF-κB harmonization

NRF-201R

Redox support architecture.

Function:

• Nrf2 support
• Oxidative injury reduction

ECM-201P

Structural preservation architecture.

Function:

• Matrix stabilization
• Elastin preservation
• Collagen homeostasis

VI. TRANSLATIONAL BIOMARKER STRATEGY

Tier I — Mechanistic Biomarkers

Target Engagement

Tier II — Disease Modification Biomarkers

Tier III — Clinical Biomarkers

VII. CLINICAL TRANSLATION STRATEGY

Phase Ia

Objectives

• Safety
• Tolerability
• PK

Population

Stable adult CF patients.

Endpoints

• Adverse events
• Lung exposure
• Plasma exposure

Phase Ib

Objectives

Proof of mechanism.

Biomarkers

• Elastase
• IL-8
• MMP-9

Phase IIa

Objectives

Proof of concept.

Primary Endpoint

Reduction in sputum elastase activity.

Secondary Endpoints

• FEV1
• Exacerbation frequency
• Biomarker improvement

VIII. REGULATORY BLUEPRINT

Following FDA development pathways.

Designation Opportunities

Orphan Drug

Strong applicability.

Fast Track

Potential applicability.

Breakthrough Therapy

Potential if substantial benefit demonstrated.

Development Sequence

Hit Identification
      ↓
Lead Optimization
      ↓
Candidate Selection
      ↓
GLP Toxicology
      ↓
Pre-IND Meeting
      ↓
IND Submission
      ↓
Phase I
      ↓
Phase II
      ↓
Phase III
      ↓
NDA

IX. CMC TRANSLATIONAL PACKAGE

Drug Substance Goals

• Manufacturable synthesis
• Scalable route
• Stable impurity profile

Drug Product Goals

Primary

Dry powder inhalation

Backup

Nebulized liposomal formulation

Shelf-Life Goal

≥24 months

X. COMMERCIAL POSITIONING

Competitive Differentiation

Current CF therapies primarily address:

• CFTR dysfunction

AEROVIA-201 addresses:

• Protease-driven lung destruction

Potential differentiation:

First-in-Class

Localized elastase regulatory therapy specifically designed for residual CF lung injury.

XI. SCF CLINICAL SUCCESS MODEL

Preventative

Prevent progression of airway structural collapse.

Curative

Reduce active protease-mediated tissue injury.

Restorative

Preserve ECM architecture and long-term lung function.

XII. PROGRAM READINESS ASSESSMENT

XIII. FINAL PHASE 8 OUTCOME

SCF ETHNOBIOPROSPECTING WORKFLOW STATUS

COMPLETED

Phases Completed:

✓ Phase 1 — Ethnopharmacological Scouting

✓ Phase 2 — Compound Extraction & SCF Analysis

✓ Phase 3 — Synergy Metrics Computation

✓ Phase 4 — SCF Fibonacci Stack Design

✓ Phase 5 — Reverse Engineering & Pathway Alignment

✓ Phase 6 — Formulation Design & PK Modeling

✓ Phase 7 — Resistance Prevention & Safety Modeling

✓ Phase 8 — Translational Blueprinting

NEXT RECOMMENDED DEVELOPMENT PROGRAM

SCF API DISCOVERY EXPANSION PROGRAM

The next logical development stage would be:

STAGE 9 — HIT IDENTIFICATION & MOLECULAR SCAFFOLD ENGINEERING

This would involve:

1. Defining actual chemical scaffold families.
2. Generating medicinal chemistry series.
3. Developing structure–activity hypotheses.
4. Establishing target-engagement assays.
5. Ranking candidate chemotypes for optimization.

Because no actual lead compound has yet been discovered, Stage 9 would remain a research-planning exercise until supported by experimental medicinal chemistry and biological screening.

MASTER REGISTRY INDEX

SCF-CF-AEROVIA201-EBP-P8-0001 — Translational Blueprinting

SCF-CF-API-201 — AEROVIA-201 Pulmonary Neutrophil Elastase Modulator

SCF-ETHBIO-WF-0001 — SCF Ethnobioprospecting Workflow

SCF-SEF-MD-0001 — Synergistic Evaluation Framework

SCF-PATH-UT-0001 — SCF Pathophysiology Protocol

SCF-PKPD-0001 — Pharmacokinetic & Pharmacodynamic Framework

SCF-CMC-0001 — Chemistry, Manufacturing & Controls Framework

SCF-FDA-IND-0001 — FDA Translational Development Framework

SCF-PCR-0001 — Preventative–Curative–Restorative Architecture